Imatinib might constitute a treatment option for lung involvement in COVID-19

Bello, David; Jaenes‐Barrios, Beatriz; Morales‐Ortega, Alejandro; Ruiz‐Giardín, José Manuel; García-Bermúdez, Virginia; Frutos‐Pérez, Begoña; Farfán-Sedano, Ana Isabel; Ancos-Aracil, C. de; Bermejo, Fernando; García‐Gil, Mario; Zapatero-Gaviria, Antonio; Martín‐López, Juan Víctor San

doi:10.1016/j.autrev.2020.102565

Cited by 24 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drugs Setrobuvir and Cefuroxime effectively bind to the SARS-CoV-2 RdRp in silico and hence can be used for treatment against the virus [ 107 ]. Similar findings were observed for Ribavirin, Sofosbuvir, Galidesivir, and Tenofovir [ 119 ]. Another in silico study reported that Rivaroxaban, Saquinavir, Tadalafil, Sildenafil, Dasatinib inhibits the SARS-CoV-2 3CL protease.…”

Section: Available Repurposed Drugs Against Covid-19supporting

confidence: 85%

See 1 more Smart Citation

COVID-19, cytokines, inflammation, and spices: How are they related?

et al. 2021

View full text Add to dashboard Cite

Background Cytokine storm is the exaggerated immune response often observed in viral infections. It is also intimately linked with the progression of COVID-19 disease as well as associated complications and mortality. Therefore, targeting the cytokine storm might help in reducing COVID-19-associated health complications. The number of COVID-associated deaths (as of January 15, 2021; https://www.worldometers.info/coronavirus/ ) in the USA is high (1199/million) as compared to countries like India is low (110/million). Although the reason behind this is not clear, spices may have some role in explaining this difference. Spices and herbs are used in different traditional medicines, especially in countries such as India to treat various chronic diseases due to their potent antioxidant and anti-inflammatory properties. Aim To evaluate the literature available on the anti-inflammatory properties of some spices which might prove beneficial in the prevention and treatment of COVID-19 associated cytokine storm. Method A detailed literature search has been conducted on PubMed for collecting information pertaining to the COVID-19; the history, origin, key structural features, and mechanism of infection of SARS-CoV-2; the repurposed drugs in use for the management of COVID-19 and the anti-inflammatory role of spices to combat COVID-19 associated cytokine storm. Key findings The literature search resulted in numerous in vitro , in vivo and clinical trials that have reported the potency of spices to exert anti-inflammatory effects by regulating crucial molecular targets for inflammation. Significance As spices are derived from Mother Nature and are inexpensive, they are relatively safer to consume. Therefore, their anti-inflammatory property can be exploited to combat the cytokine storm in COVID-19 patients. This review thus focuses on the current knowledge on the role of spices for the treatment of COVID-19 through suppression of inflammation-linked cytokine storm.

show abstract

Section: Available Repurposed Drugs Against Covid-19supporting

confidence: 85%

“…Further, it also exhibits anti-viral effects against SARS-CoV and MERS-CoV. Therefore, it is believed that Imatinib might also be effective against SARS-CoV-2 and have an immunomodulatory effect against COVID-19 pneumonia [ 119 , 177 ]. Lactoferrin exerts immunomodulatory and anti-inflammatory properties.…”

Section: Available Repurposed Drugs Against Covid-19mentioning

confidence: 99%

COVID-19, cytokines, inflammation, and spices: How are they related?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For instance, Goker et al has revealed that ruxolitinib shows the promising efficacy on COVID-19 by inhibiting JAK/STAT pathway ( Goker Bagca and Biray Avci, 2020 ). Imatinib might play its potentially beneficial immunomodulatory role in patients with COVID-19 by multiple mechanisms, such as reducing the transcription factor NF-κB signaling pathway and modulating tumor necrosis factor-α (TNF-α) and IL-6 production ( Bernal-Bello et al, 2020 ). However, according to the network analysis, the COVID-19 ongoing drugs could act on multiple targets, including both CoV and non-CoV host proteins.…”

Section: Resultsmentioning

confidence: 99%

Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspective

Fan

Hong

et al. 2020

Food and Chemical Toxicology

View full text Add to dashboard Cite

Currently, coronavirus disease 2019 (COVID-19), has posed an imminent threat to global public health. Although some current therapeutic agents have showed potential prevention or treatment, a growing number of associated adverse events have occurred on patients with COVID-19 in the course of medical treatment. Therefore, a comprehensive assessment of the safety profile of therapeutic agents against COVID-19 is urgently needed. In this study, we proposed a network-based framework to identify the potential side effects of current COVID-19 drugs in clinical trials. We established the associations between 116 COVID-19 drugs and 30 kinds of human tissues based on network proximity and gene-set enrichment analysis (GSEA) approaches. Additionally, we focused on four types of drug-induced toxicities targeting four tissues, including hepatotoxicity, renal toxicity, lung toxicity, and neurotoxicity, and validated our network-based predictions by preclinical and clinical evidence available. Finally, we further performed pharmacovigilance analysis to validate several drug-tissue toxicities via data mining adverse event reporting data, and we identified several new drug-induced side effects without labeling in Food and Drug Administration (FDA) drug instructions. Overall, this study provides forceful approaches to assess potential side effects on COVID-19 drugs, which will be helpful for their safe use in clinical practice and promoting the discovery of antiviral therapeutics against SARS-CoV-2.

show abstract

“… 228 This information insinuates that such drug might perform its potentially beneficial immunomodulatory role as a treatment alternative for COVID-19 pneumonia. In addition, the use of imatinib as treatment appears to be reasonable from an economic point of view and its high availability in hospitals, 229 since this drug is well tolerated and the risk of severe adverse effects is relatively low, especially in short-term administration. 230 It is also recognized that adverse effects, mostly mild to moderate in intensity, will be easily controlled by dose reduction or discontinuation.…”

Section: Drug Repurposing For Covid-19mentioning

confidence: 99%